Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy

NEW YORK, Oct. 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy
http://www.reportlinker.com/p01020575/Hepatitis-C-Therapeutics-Market-to-2018---Expected-Launch-of-GS-7977-in-2015-will-Pave-the-Way-for-an-Oral-Interferon-free-Combination-Therapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy", which provides insights into the global hepatitis C therapeutics market up to 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report examines the global hepatitis C treatment usage patterns, and the geographical distribution of hepatitis C therapeutics and markets across the US, the top five countries of Europe and Japan. The report also includes insights into the hepatitis C therapeutics R&D product pipeline and explores the competitive landscape, including major players in the hepatitis C therapeutics market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that took place in the hepatitis C therapeutics market from 2010 to 2012.

In 2011, the hepatitis C therapeutics market was estimated at $2.6 billion. From 2004 to 2011, the market grew at the CAGR of 2.7%, with the launch of Incivek and Victrelis in 2011 boosting positive growth. The market had seen a significant decline in value due to the low uptake of Pegylated Interferon (PI) therapies and subsequent patient warehousing in anticipation of more effective drugs being launched. The launch of the two PIs added a billion dollars to the market in 2011 and helped to achieve a positive CAGR. GBI Research analyses estimate that the hepatitis C therapeutics market in the top seven markets will be valued at $14.9 billion in 2018, with a CAGR of 28.3% over the forecast period. These estimates are based on the continued adoption of PIs as the gold standard treatment option for hepatitis C, and the imminent launch of oral DAA molecules, the first of which should be in the market in 2015. Further, combinations of DAA drugs will improve the overall effectiveness of treatment and will have less side-effects than PIs. This should result in a significant increase in diagnosis and treatment rates over the forecast period.

Scope

- Data and analysis on the hepatitis C therapeutics market in the leading geographies of the world – the US, Japan, the UK, Germany, France, Italy and Spain.
- Annualized market data for the hepatitis C therapeutics market from 2004 to 2011, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global hepatitis C therapeutics market including top companies benchmarking. The key companies studied in this report are Vertex Pharmaceuticals, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company (BMS), Abbott Laboratories, F. Hoffmann-La Roche Ltd., Johnson & Johnson / Tibotec BVBA, Boehringer Ingelheim GmbH, Novartis AG, Achillion Pharmaceuticals, Inc., and Idenix Pharmaceuticals, Inc.
- Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the hepatitis C therapeutics market.

Reasons to buy

- Align their product portfolios to markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.



1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
3 Market Overview 11
3.1 Introduction 11
3.1.1 HCV Classification 11
3.1.2 HCV Genome 12
3.1.3 HCV Diagnosis 13
3.1.4 HCV Treatment Goals 13
3.1.5 Current HCV Treatment Options 15
3.1.6 Future HCV Treatment Paradigm 16
3.2 Global Hepatitis C Therapeutics Market 18
3.2.1 Revenue 18
3.2.2 Annual Cost of Therapy 22
3.2.3 Treatment Usage Pattern 23
3.2.4 Market Trends 26
4 Geographic Landscape 27
4.1 The US 27
4.1.1 Revenue 27
4.1.2 Annual Cost of Therapy 28
4.1.3 Treatment Usage Pattern 29
4.2 Top Five Countries of Europe 31
4.2.1 Revenue 31
4.2.2 Revenue by Country 33
4.2.3 Annual Cost of Therapy 35
4.2.4 Treatment Usage Pattern 36
4.3 Japan 38
4.3.1 Revenue 38
4.3.2 Annual Cost of Therapy 39
4.3.3 Treatment Usage Pattern 40
4.4 Other Markets 42
4.4.1 Australia 42
4.4.2 China 46
4.4.3 India 49
5 Pipeline Analysis 52
5.1 Research and Development Pipeline 52
5.2 Highlights from the International Liver Congress 2012, European Association for the Study of the Liver 53
5.3 Recently Launched 55
5.3.1 Incivek/Telavic/Incivo (telaprevir) 55
5.3.2 Victrelis 58
5.3.3 Perspective on Incivek and Victrelis 59
5.4 Most Promising Molecules in Phase III 61
5.4.1 GS-7977 61
5.4.2 BMS-790052 (daclatasvir) 67
5.4.3 TMC-435 68
5.4.4 BI-201335 70
5.5 Most Promising Molecules in Phase II 73
5.5.1 ABT-450 73
5.5.2 GS-5885 74
5.5.3 RG7128 (mericitabine) 74
5.5.4 ACH-1625 75
5.6 Combination Therapy Development 76
5.6.1 With PEG-IFN and RBV 76
5.6.2 With RBV only 77
5.6.3 Without PEG-IFN and RBV 78
6 Competitive Landscape 80
6.1 Market Share Analysis 80
6.2 Competitive Profiling 81
6.2.1 Vertex Pharmaceuticals, Inc. 81
6.2.2 Merck & Co., Inc. 82
6.2.3 Gilead Sciences, Inc. 84
6.2.4 Bristol-Myers Squibb Company 85
6.2.5 Abbott Laboratories 87
6.2.6 F. Hoffmann-La Roche Ltd. 88
6.2.7 Johnson & Johnson/Tibotec BVBA 89
6.2.8 Boehringer Ingelheim GmbH 91
6.2.9 Novartis AG 92
6.2.10 Achillion Pharmaceuticals, Inc. 93
6.2.11 Idenix Pharmaceuticals, Inc. 94
7 Strategic Consolidations 95
7.1 Deals by Year 96
7.2 Deals by Type 97
7.3 Deals by Value 98
7.4 Deals by Region 99
7.5 Mergers and Acquisitions 100
7.5.1 Major M&A Deals 101
7.6 Licensing Agreements 102
7.6.1 Major Licensing Agreements 103
7.7 Partnerships 104
7.7.1 Major Partnership Deals 105
8 Appendix 106
8.1 Market Definitions 106
8.2 Abbreviations 106
8.3 Bibliography 107
8.4 Research Methodology 108
8.4.1 Coverage 108
8.4.2 Secondary Research 109
8.4.3 Primary Research 109
8.4.4 Therapeutic Landscape 110
8.4.5 Market Size by Geography 112
8.4.6 Geographical Landscape 113
8.4.7 Pipeline Analysis 113
8.4.8 Competitive Landscape 113
8.4.9 Expert Panel Validation 113
8.5 Contact Us 113
8.6 Disclaimer 113

1.1 List of Tables

Table 1: Characteristics of HCV Genotypes 1–3 12
Table 2: Functions of HCV Proteins and Therapeutic Approach 12
Table 3: Clinical Endpoints for HCV Therapy 14
Table 4: Patient Classification Based on Viral Response to Therapy 14
Table 5: Direct-acting Antiviral Therapies in Development 16
Table 6: Host-Targeting Antiviral Therapies in Development 17
Table 7: Novel Interferons in Development 17
Table 8: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2004–2011 18
Table 9: Hepatitis C Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 18
Table 10: Hepatitis C Therapeutics Market, Global, Revenues by Geography ($m), 2004–2011 20
Table 11: Hepatitis C Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011–2018 20
Table 12: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2004–2011 22
Table 13: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2018 22
Table 14: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2004–2011 24
Table 15: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2011–2018 24
Table 16: Hepatitis C Therapeutics Market, The US, Revenues ($m), 2004–2011 27
Table 17: Hepatitis C Therapeutics Market, The US, Revenue Forecasts ($m), 2011–2018 27
Table 18: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2004–2011 28
Table 19: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2018 28
Table 20: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2004–2011 30
Table 21: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2011–2018 30
Table 22: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2004–2011 32
Table 23: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011–2018 32
Table 24: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenues by Country ($m), 2004–2011 33
Table 25: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($m), 2011–2018 34
Table 26: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004–2011 35
Table 27: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011–2018 35
Table 28: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2004–2011 36
Table 29: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2011–2018 37
Table 30: Hepatitis C Therapeutics Market, Japan, Revenue ($m), 2004–2011 38
Table 31: Hepatitis C Therapeutics Market, Japan, Revenue Forecasts ($m), 2011–2018 38
Table 32: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004–2011 39
Table 33: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2018 39
Table 34: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2004–2011 40
Table 35: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2011–2018 41
Table 36: Hepatitis C Therapeutics Market, Australia, Pipeline Analysis, 2012 43
Table 37: Hepatitis C Therapeutics Market, China, Factors Associated with HCV Infection 47
Table 38: Hepatitis C Therapeutics Market, China, Pipeline Analysis, 2012 49
Table 39: Hepatitis C Therapeutics Market, India, Pipeline Analysis, 2012 51
Table 40: Hepatitis C Therapeutics Market, Global, Notable Interferon-free Therapy Regimens Presented at EASL 2012 53
Table 41: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Recently Launched Products, 2012 55
Table 42: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ADVANCE Phase III Study Results 56
Table 43: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ILLUMINATE Phase III Study Results 56
Table 44: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, REALIZE Phase III Study Results 57
Table 45: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules in Phase III, 2012 61
Table 46: Hepatitis C Therapeutics Market, Global, GS-7977, Phase III Program 61
Table 47: Hepatitis C Therapeutics Market, Global, GS-7977, The QUANTUM Study Results 62
Table 48: Hepatitis C Therapeutics Market, Global, GS-7977, The ELECTRON Study Results 63
Table 49: Hepatitis C Therapeutics Market, Global, GS-7977, Partnership with BMS-790052, Study Results 66
Table 50: Hepatitis C Therapeutics Market, Global, TMC-435, The Phase III Program 68
Table 51: Hepatitis C Therapeutics Market, Global, TMC-435, ASPIRE Study, Efficacy Results 69
Table 52: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C1 Study Results 71
Table 53: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Efficacy Results 72
Table 54: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Safety Results 72
Table 55: Hepatitis C Therapeutics Market, Global, BI-201335, The SOUND-C2 Study Results 72
Table 56: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules in Phase II, 2012 73
Table 57: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies with PEG-IFN and RBV, 2012 76
Table 58: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies with RBV, 2012 77
Table 59: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies without PEG-IFN and RBV, 2012 78
Table 60: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Mergers and Acquisitions, 2010–2012 100
Table 61: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Licensing Agreements, 2010–2012 102
Table 62: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Partnerships, 2010–2012 104

1.2 List of Figures

Figure 1: Hepatitis C, Global, Prevalence (million) and Genotype Distribution, 2011 11
Figure 2: Hepatitis C Therapeutics Market, Global, Revenue Forecasts ($m), 2004–2018 18
Figure 3: Hepatitis C Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2004–2018 19
Figure 4: Hepatitis C Therapeutics Market, Global, Branded and Generic Product Share (%), 2011 and 2018 21
Figure 5: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2004–2018 22
Figure 6: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2004–2018 23
Figure 7: Hepatitis C Therapeutics Market to 2018, Global, Market Trends, Drivers and Barriers 26
Figure 8: Hepatitis C Therapeutics Market, The US, Revenue Forecasts ($m), 2004–2018 27
Figure 9: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2004–2018 28
Figure 10: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2004–2018 29
Figure 11: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2004–2018 31
Figure 12: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($m), 2004–2018 33
Figure 13: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004–2018 35
Figure 14: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2004–2018 36
Figure 15: Hepatitis C Therapeutics Market, Japan, Revenue Forecasts ($m), 2004–2018 38
Figure 16: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004–2018 39
Figure 17: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2004–2018 40
Figure 18: Hepatitis C Therapeutics Market, China, Revenue ($m), 2007–2011 48
Figure 19: Hepatitis C Therapeutics Market, India, Revenue ($m), 2007–2011 50
Figure 20: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Molecules in Development by Phase, May 2012 52
Figure 21: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ADVANCE Phase III Study Design 55
Figure 22: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ILLUMINATE Phase III Study Design 56
Figure 23: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, REALIZE Phase III Study Design 57
Figure 24: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Victrelis, SPRINT-2 Phase III Study Design 58
Figure 25: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Victrelis, RESPOND-2 Phase III Study Design 59
Figure 26: Hepatitis C Therapeutics Market, Global, GS-7977, The QUANTUM Study Design 62
Figure 27: Hepatitis C Therapeutics Market, Global, GS-7977, The ELECTRON Study Design 63
Figure 28: Hepatitis C Therapeutics Market, Global, GS-7977, The PROTON Study Design 64
Figure 29: Hepatitis C Therapeutics Market, Global, GS-7977, The ATOMIC Study Design 65
Figure 30: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C1 Study Design 70
Figure 31: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Results 71
Figure 32: Hepatitis C Therapeutics Market, Global, Mericitabine, The PROPEL Study Design 74
Figure 33: Hepatitis C Therapeutics Market, Global, Mericitabine, The INFORM-SVR Study Design 75
Figure 34: Hepatitis C Therapeutics Market, Global, Competitive Landscape, Market Share (%), 2011 80
Figure 35: Hepatitis C Therapeutics Market, Global, Vertex Pharmaceuticals, SWOT Analysis 82
Figure 36: Hepatitis C Therapeutics Market, Global, Merck and Co., SWOT Analysis 83
Figure 37: Hepatitis C Therapeutics Market, Global, Gilead Sciences, SWOT Analysis 85
Figure 38: Hepatitis C Therapeutics Market, Global, Bristol-Myers Squibb Company, SWOT Analysis 86
Figure 39: Hepatitis C Therapeutics Market, Global, Abbott Laboratories, SWOT Analysis 88
Figure 40: Hepatitis C Therapeutics Market, Global, F. Hoffmann-La Roche, SWOT Analysis 89
Figure 41: Hepatitis C Therapeutics Market, Global, Johnson & Johnson/Tibotec, SWOT Analysis 90
Figure 42: Hepatitis C Therapeutics Market, Global, Boehringer Ingelheim, SWOT Analysis 91
Figure 43: Hepatitis C Therapeutics Market, Global, Novartis, SWOT Analysis 92
Figure 44: Hepatitis C Therapeutics Market, Global, Achillion Pharmaceuticals, SWOT Analysis 93
Figure 45: Hepatitis C Therapeutics Market, Global, Idenix Pharmaceuticals, SWOT Analysis 94
Figure 46: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Year, 2010–2012 96
Figure 47: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Type, 2010–2012 97
Figure 48: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Value, 2010–2012 98
Figure 49: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Region, 2010–2012 99
Figure 50: GBI Research Market Forecasting Model 112

Companies mentioned
Vertex Pharmaceuticals, Inc.
Merck & Co., Inc.
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Johnson & Johnson/Tibotec BVBA
Boehringer Ingelheim GmbH
Novartis AG
Achillion Pharmaceuticals, Inc.
Idenix Pharmaceuticals, Inc.





To order this report:
Therapy Industry: Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker